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Background: Herpes Simplex Virus Type 2 (HSV-2) is highly prevalent in regions disproportionately affected by the
human immunodeficiency virus (HIV-1) epidemic. The objective of our study was to identify the risk factors of HSV-2
and HIV-1 infections and to examine the association between the two infections.
Methods: The study participants were recruited through a community based cross-sectional study that was
conducted from November 2002 to March 2003 in the Moshi urban district of Northern Tanzania. A two-stage
sampling design was used in recruiting the study participants. Information on socio-demographics, alcohol use,
sexual behaviors, and STIs symptoms were obtained. Blood and urine samples were drawn for testing of HIV-1,
HSV-2 and other STIs.
Results: The prevalence of HSV-2 infection among all study participants was 43%. The prevalence rate of HSV-2
among the HIV-negative and HIV-positive women was 40% and 65%, respectively. We found 2.72 times odds of
having HIV-1 in an HSV-2 positive woman than in an HSV-2 negative woman. Furthermore, HIV-1 and HSV-2 shared
common high-risk sexual behavior factors such as early onset of sexual debut, and testing positive for other STIs.
Conclusions: Our findings suggest that HSV-2 may be both a biological and risk-associated cofactor for HIV-1
acquisition. In resource-limited countries, where both infections are prevalent efforts at symptomatic and diagnostic
screening and treatment of HSV-2 should be part of HIV-1 prevention programs.Background
The correlate of herpes simplex type 2 (HSV-2) and human
immunodeficiency virus type 1 (HIV-1) epidemics is intri-
guing and has been the subject of several studies. HSV-2 is
a common infection, with an estimated prevalence and inci-
dence of 536 and 23.6 million infections, respectively, in
15 – 49-year-olds worldwide [1]. HSV-2 infection is highly
prevalent in regions disproportionately affected by the
HIV-1 epidemic. Several epidemiological studies have
demonstrated higher incidence and prevalence rates of
HIV-1 among HSV-2-infected populations and vice versa
[2-5]. Sub-Saharan Africa with the highest prevalence of
HIV-1 has about 80% prevalence rate of HSV-2 among its* Correspondence: Musie_Ghebremichael@DFCI.HARVARD.EDU
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distribution, and reproduction in any mediumadult population [6,7]. The prevalence of HSV-2 in HIV-
infected individuals in sub-Saharan Africa is 50 to 90% [8].
Furthermore, there is a high seroprevalence of HSV-2 in
communities with high incidence of HIV-1 in developed
countries [9,10]. The similarities between the two infections
with regard to prevalence rates, risk factors, and geograph-
ical distribution cannot be a mere coincidence. If the asso-
ciation between HSV-2 infection and HIV-1 is causal, then
the proportion of HIV infections attributable to HSV-2 in-
fection is high, estimated at 25% –35% in sub-Saharan
Africa [11]. Thus, the high prevalence of HSV-2 and its
interaction with HIV-1 might have played a significant role
in the HIV-1 epidemic in sub-Saharan Africa.
Several epidemiological and laboratory studies have sug-
gested a biological plausibility of HSV-2 infection facilitat-
ing the acquisition and transmission of HIV-1. Recurrent
episodes of HSV-2 may increase the susceptibility to HIV-1Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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target cells in the genital tract [8,12,13]. In HIV-1-
serodiscordant couples, HSV-2-seropositive individuals
were at increased risk of acquiring HIV-1 [14,15]. In indivi-
duals with HIV-1 and HSV-2 co-infection, symptomatic
and asymptomatic reactivation of HSV-2 has been asso-
ciated with increased plasma HIV-1 viral load and genital
shedding of HIV-1 [16]. To establish a relationship be-
tween HSV-2 and HIV-1 replication, several randomized
controlled trails have tested the effect of HSV-2 suppres-
sive therapy on HIV-1 transmission [14,17-20]. Unfortu-
nately, the effect of HSV-2 suppressive therapy - with
acyclovir - on HIV-1 transmission in these studies has been
mixed. However, most of these studies demonstrated a re-
duction in plasma and genital HIV-1 RNA concentrations
in co-infected individuals. Acyclovir, used in these trials,
has direct anti-HIV effect by inhibiting HIV-1 reverse tran-
scriptase [21,22]. Therefore, it has been argued that the
modest effect on HIV replication seen in these trials may
not be directly related to HSV-2-HIV-1 interaction. More-
over, the mixed reports might be due to the rather complex
nature of the interaction between the two pathogens and
the fact that both epidemics have matured and reached sat-
uration making it difficult to tease out the relationship by
clinical trials.
We hypothesized that HSV-2 epidemic might have con-
tributed to the evolution of the HIV epidemic in sub-
Saharan Africa. To test this hypothesis, we used data from
a community-based survey in the Moshi urban district of
northern Tanzania. The prevalence of HSV-2 in Tanzania
is estimated at 70% [23]. However, in the study cohort, the
prevalence of HSV-2 and HIV-1 are 43% and 11%, re-
spectively [24]. The objectives of our study were: 1) to
identify shared-risk factors of HSV-2 and HIV-1 infections
and 2) to examine the association between HIV-1 and
HSV-2 among study participants.
Methods
Study design
A detailed description of the study design and characteris-
tics of the study participants has been described previously
[24]. In brief, the study participants were recruited
through a community based cross-sectional study that
was conducted from November 2002 to March 2003 in
the Moshi urban district of Northern Tanzania. A two-
stage sampling design was used in recruiting the study
participants. First, 150 geographic clusters were randomly
selected from Moshi and then a number of households
were randomly selected from each cluster. A total of 2019
women who were residents of the households and 794
men who were their partners were enrolled into the study.
The participants’ socio-demographic, high-risk behavior,
biological, and medical characteristics were assessed. The
study was approved by the Harvard School of PublicHealth IRB (HSC Protocol #0108ACOM), University of
Maryland IRB (Protocol #05-0031), Kilimanjaro Christian
Medical Center Ethics Committee, Research and Ethical
Clearance of the Tanzanian National Institute for Medical
Research, the Centers for Disease Control and Prevention
Institutional Review Board. Written informed consent for
participation in the study was obtained from participants.
Laboratory methods
Blood and urine samples were collected and tested for
HIV-1, HSV-2 and other sexually transmitted infections
(STIs). HIV-1 infection was determined using HIV
enzyme-linked immunosorbent assay (ELISA) (Vironos-
tika HIV Uni-Form II Plus O, Organon, Boxtel, The
Netherlands) and reactive samples were confirmed using
Wellcozyme HIV-1 ELISA test (Murex 1.2.0, Murex Bio-
tech Ltd., UK). Western blot tests (Bio-Rad Laboratories
Ltd., Dartford, UK) were used to confirm discordant
ELISA test results. Antibodies to HSV-2 were detected
using enzyme immune assay (EIA) according to the
manufacturer’s instructions (HerpeSelect 2 ELISA, Focus
Technologies, Cypress, CA). Active and past syphilis
were diagnosed if the serum was reactive on the Rapid
Plasma Reagin card test (Macro-Vue; Becton-Dickinson,
Cockeysville, MD) and/or the Treponema Pallidum
xHemagglutination Assay (TPHA) (Wecosyph HA;
Murex Bio-tech Ltd., UK). Urine samples were tested for
Chlamydia, gonorrhea, trichomonas and mycoplasma
genitalium by using a real-time multiplex polymerase
chain reaction (M-PRC) assay.
Study measures
Socio-demographic characteristics (e.g., age in years, re-
ligion, ethnicity, education), high-risk behaviors (e.g., age
at first sex, number of sexual partners in the previous
three years, alcohol use, condom use), and biological/
medical factors (e.g., circumcision, symptoms of STIs
and STIs other than HIV-1/HSV-2) were considered as
covariates in our analyses. Alcohol abuse was measured
by the CAGE score. An STI’s symptom was defined as
having at least one of the following symptoms: abdom-
inal pain, abnormal genital discharge, foul smell in the
genital area, excessive genital secretions, swellings in the
genital area, itching in the genital area, burning pain on
micturition, pain during intercourse, and genital ulcers.
Statistical methods
We have a clustered binary data with individuals (level-1),
i.e., women, nested in geographic clusters (level-2). It is rea-
sonable to assume that measurements from individuals
within the same cluster were correlated. Because of the in-
herent intra-cluster correlation between binary outcomes,
statistical modelling of the data using the ordinary logistic re-
gression is not appropriate. Therefore, multilevel generalized
Table 1 Herpes simplex virus type-2 and HIV-1 prevalence by socio-demographic, high risk behavior, biological and
medical factors among women in Moshi district, northern Tanzania
Variables HSV-2 (N= 1418) HIV-1 (N = 1418)
Negative N (%) Positive N (%) P-value Negative N (%) Positive N (%) P-value
Age <0.01 0.04
20-24 354 (44) 99 (16) 419 (33) 34 (22)
25-29 205 (25) 140 (23) 303 (24) 42 (27)
30-34 119 (15) 140 (23) 228 (18) 31 (20)
35-39 78 (10) 120 (20) 168 (13) 30 (20)
≥ 40 52 (6) 109 (18) 144 (12) 17 (11)
Ethnicity 0.18 0.56
Chaga 438 (54) 301 (49) 665 (53) 74 (48)
Pare 98 (12) 77 (13) 154 (12) 21 (14)
Other 272 (34) 231 (38) 44 4(35) 59 (38)
Religion 0.05 0.54
Muslim/other 255 (32) 229 (38) 430 (34) 54 (35)
Catholic 332 (41) 237 (39) 503 (40) 66 (43)
Protestant 221 (27) 143 (23) 330 (26) 34 (22)
Education 0.52 0.34
Pre-secondary 622 (77) 477 (78) 975 (77) 124 (81)
Secondary and above 187 (23) 132 (22) 289 (23) 30 (19)
Alcohol abuse 0.71 0.82
No 296 (84) 291 (85) 508 (85) 79 (84)
Yes 55 (16) 50 (15) 90 (15) 15 (16)
Number of partners† 0.26 <0.01
1 587 (90) 492 (88) 967 (91) 112 (79)
2+ 64 (10) 66 (12) 100 (9) 30 (21)
Age at first sex <0.01 <0.01
<18 222 (28) 248 (42) 392 (32) 78 (52)
18-19 215 (27) 159 (27) 339 (27) 35 (23)
20+ 353 (45) 188 (31) 503 (41) 38 (25)
Condom use{ 0.85 0.27
Never 500 (77) 429 (77) 826 (78) 103 (75)
Sometimes 133 (21) 115 (21) 218 (20) 30 (22)
Often/always 11 (2) 12 (2) 18 (2) 5 (3)
Female circumcision 0.06 0.98
No 624 (77) 442 (73) 950 (75) 116 (75)
Yes 185 (23) 166 (27) 313 (25) 38 (25)
Test positive STIs* <0.01 <0.01
Negative 715 (88) 500 (82) 1098 (87) 117 (76)
Positive 94 (12) 109 (18) 166 (13) 37 (24)
STIs Symptoms 0.06 0.04
No 498 (71) 392 (66) 797 (70) 93 (62)
Yes 204 (29) 201 (34) 347 (30) 58 (38)
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Table 1 Herpes simplex virus type-2 and HIV-1 prevalence by socio-demographic, high risk behavior, biological and
medical factors among women in Moshi district, northern Tanzania (Continued)
HSV-2 - <0.01
No - - 755 (60) 54 (35)
Yes - - 509 (40) 100 (65)
*Syphilis, Chlamydia, gonorrhea, trichomonas and mycoplasma genitalium.
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the risk factors for both infections and the interplay be-
tween them. The correlation among individuals from the
same cluster was incorporated using a random intercept
at the cluster level. Measurements from individuals within
the same cluster were assumed to be independent given
the random intercept. Model parameters were estimated
via maximum likelihood based on adaptive quadrature
[25]. The analysis was performed using the GLIMMIX
procedure in SAS [26].Results
Characteristics of study participants by their HSV-2 and
HIV-1 status
Among the 1418 women who provided blood samples,
154 and 609 were seropositive for HIV-1 and HSV-2, re-
spectively. The prevalence rate of HSV-2 among the
women who tested positive for HIV-1 was 65%, which
was 1.63 times higher than the rate of HSV-2 in women
who tested negative for HIV-1. Preliminary analysis was
done using Pearson’s Chi-square and Fisher’s exact tests
to identify the potential risk factors of HSV-2 and HIV-1
infections (Table 1). Table 1 presents participants’ socio-
demographic, risk behavior and medical/biological char-
acteristics by their HSV-2 and HIV-1 infection status.
The prevalence of both HSV-2 (p < 0.01) and HIV-1
(p = 0.04) was significantly associated with the age of the
participant. Religion was significantly associated with
HSV-2 (p = 0.05) but not with HIV-1 (p = 0.54). HSV-2
prevalence rate was lower for Protestants compared to
that of the other religions/denominations. Number of
sexual partners in the previous three years was asso-
ciated with HIV-1 (p < 0.01) but not with HSV-2
(p = 0.26). HSV-2 and HIV-1 prevalence rates were sig-
nificantly associated with age at first sex (p < 0.01), with
higher rates among women who experienced an early
sexual debut. That is, postponing age at first sexual
debut was protective for both infections. Having a posi-
tive test for STI (e.g., syphilis, chlamydia, gonorrhea, tri-
chomonas and mycoplasma genitalium) was significantly
associated with HSV-2 and HIV-1 status (p < 0.01).
There was a significant association between having
symptoms of STIs at study enrolment and HIV-1 status
(p = 0.04). However, the association between symptoms
of STIs and HSV-2 status was only marginally significant
(p = 0.06). HSV-2 status was significantly associated withHIV-1 status (p < 0.01). Female circumcision, alcohol use
and condom use were not associated with either HIV-1
or HSV-2 infection status.Multivariate analysis: risk factors for HSV-2 and HIV-1 and
effect of HSV-2 on HIV-1
Multivariate analysis using multilevel generalized linear
mixed effects models - with women nested in geographic
clusters - were fitted. All the variables that were found
to be significantly associated with HIV-1 and HSV-2 at
0.30 levels in the univariate analysis were included as
covariates in the multivariate analysis. The results of the
multivariate analyses are reported in Figures 1, 2.
The adjusted results in Figures 1, 2 indicate that older
women were more likely to have HSV-2 compared to
younger women. For example, the odds of having HSV-2
in a woman 40 years or older was 9.88 times higher than
that of woman between 20 and 24 years (OR= 9.88; 95%,
CI: 6.01-16.23). The effects of religion, ethnicity, number
of sexual partners and female circumcision on HSV-2
were not significant. However, age at sexual onset was
significantly associated with HSV-2. Women who started
their sexual debut before 18 years were more likely to
have HSV-2 that those who began to have sex at 18 to
19 years or age 20 and older (OR= 0.72, 95% CI = 0.52-
0.99; OR= 0.51, 95% CI = 0.37-0.71). Testing positive for
other STIs (OR= 1.67, 95% CI = 1.15-2.43) and having
STI symptoms (OR= 1.41, 95% CI = 1.06-1.85) were
associated with a higher prevalence of HSV-2.
Women who tested positive for HSV-2 had a higher
prevalence of HIV-1. The odds of having HIV-1 in HSV-2
positive women were 2.72 times higher than that of
women who tested negative for HSV-2 (OR=2.72; 95%,
CI: 1.77-4.21). In contrast to HSV-2, HIV-1 prevalence did
not significantly vary by the age of the woman. However,
age at sexual debut was significantly associated with HIV-
1 as observed with HSV-2. Women who had first sex at
18 to 19 years or age 20 and older were less likely to have
HIV-1 than women who had first sex before age 18
(OR=0.49, 95% CI= 0.31-0.81; OR= 0.61, 95% CI= 0.37-
0.95). Moreover, women who had two or more partners in
the previous three years (OR=2.09; 95% CI: 1.22-3.57)
were more likely to have HIV-1 compared with women
who had one partner. Furthermore, testing positive for
other STIs (OR=1.62, 95% CI= 1.01-2.61) were associated
with high prevalence of HIV-1.
Figure 1 Risk factors for HSV-2 among women in Moshi district, northern Tanzania.
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The prevalence of HSV-2 infection among all study par-
ticipants was 43%. The prevalence rate of HSV-2 among
the HIV-negative and HIV-positive women was 40% and
65%, respectively. These rates are comparable to the
rates reported in other studies from sub-Saharan Africa
[23]. We found 2.72 times odds of having HIV-1 in an
HSV-2 seropositive woman than in an HSV-2 seronega-
tive woman. Our finding is consistent with a previous
meta-analyses of cohort studies that showed that HSV-2
infection led to two to three times increase in risk ofFigure 2 Risk factors for HIV-1 among women in Moshi district, northacquiring HIV-1 [5,27,28]. Two recent cohort studies
from Uganda and Zimbabwe reported hazards ratios of
HIV-1 acquisition of 2.8 and 4.4 for prevalent HSV-2 in-
fection, respectively, and 4.6 and 8.6 for incident infec-
tion, respectively [29].
Consistent with other studies from the sub-region
[30,31], we found a direct association between HSV-2
and HIV-1 infections. Our finding of HSV-2 as a signifi-
cant predictor for HIV-1 infection coupled with findings
from other investigators that HSV-2 acquisition gener-
ally precedes HIV-1 seroconversion [30] support ourern Tanzania.
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the HIV-1 epidemic in sub-Saharan Africa. The interplay
between HIV-1 and HSV-2 infections is known to be bi-
directional and complex. From our study and that of
others, HSV-2 seems to serve as both a high-risk and
biological cofactor for HIV-1 acquisition.
HIV-1 and HSV-2 shared common high-risk sexual be-
havior factors such as early onset of sexual debut, and test-
ing positive for other STIs. Is it possible that the association
between HIV-1 acquisition and HSV-2 is confounded by
high-risk sexual behaviors placing individuals at risk for
both viruses? This concept is attractive and may help ex-
plain the inconsistent results of efficacy trials of HSV-2 sup-
pression for prevention of HIV acquisition. However, our
data will argue to the contrary. The higher prevalence of
HSV-2 and its predominance in older women suggest that
HSV epidemic predates that of HIV. Moreover, it is well
known that infection with one STI may increase the prob-
ability of acquiring or transmitting another STI. These
could be the potential reasons for the high prevalence of
HIV-1 in our study among women who were HSV-2 sero-
positive. The increased risk of HSV-2 and HIV-1 associated
with an early age at first sex may be partly due to biological,
behavioral, and socio-economic predispositions [24].
HSV-2 may serve as a biological cofactor for HIV-1
acquisition. HSV-2 creates potential biological bridges
for HIV acquisition; by erosion of the epithelial barrier
through which HIV-1 can enter and by causing localized
inflammation that leads to the recruitment of new HIV-1
susceptible targets such as activated CD4+ T-cells and
macrophages that live in the sub- epithelium [32,33]. Fur-
thermore, some HSV-2 proteins have been reported to
directly interact in vitro with HIV-1 long terminal
repeat (LTR) region to up-regulate HIV-1 replication
through NF-κB activation [34]. The above biological phe-
nomena lead to increase HIV-1 viral load in plasma and
genital secretions of individuals with HIV-1 and HSV-2
co-infection during symptomatic and asymptomatic re-
activation of HSV-2 [16].
The present study has several strengths compared to
previous studies; it has a large sample size and used
laboratory-confirmed STIs in a population based sample.
Most studies of the prevalence of HSV-2 and its role as
a risk factor for HIV have been carried out in particular
groups that are not representative of the overall popula-
tion, such as STD or antenatal clinic attendees, blood
donors, or men who have sex with men [35]. However,
our study had some limitations. A strong case for causal-
ity cannot be made given the cross-sectional nature of
the study; however, our findings reiterate the need for
further research. Longitudinal studies, taking into con-
sideration the anti-HIV effect of acyclovir, are needed to
elucidate the nature of the relationship between HSV-2
and HIV-1 infections.Conclusions
In conclusion, we found a significant association and
synergy between HSV-2 and HIV-1 infections among
study participants. HSV-2 may be a biological and risk
cofactor for HIV-1 acquisition. In resource-limited coun-
tries, where both infections are prevalent efforts at
symptomatic and diagnostic screening and treatment of
HSV-2 could be part of the preventive measures for
HIV-1. Furthermore, our study identified specific high-
risk behaviors – early onset of sexual debut, multiple
sexual partners and presence of other STIs – that could
be used in crafting messages for HIV-1 prevention
programs.
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